



# Gennex Laboratories Limited

"AKASH GANGA" 3rd Floor, Plot No.144, Srinagar Colony, Hyderabad - 500073. Telangana, INDIA  
Tel : +91-40-67334400 (30Lines), 23746451, Fax : +91-40-67334433  
Email: info@gennexlab.com | www.gennexlab.com  
CIN : L24230TG1990PLCO11168

Ref: GLL/Board/2018-19/0031

Date: 14/08/2018.

To  
Dy. General Manager,  
**Bombay Stock Exchange Ltd.,**  
Phiroje Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001.

To  
The Secretary  
**The Calcutta Stock Exchange Association Ltd.,**  
7, Lyons Range, Calcutta – 700 001.

Dear Sir/Madam,

Subject : Announcement of Un-audited financial results for the Quarter Ended  
June 30, 2018 together with the Limited Review Report of Auditors as Annexure  
– I.

Reference : Reg. 30(2) and Reg.33 of SEBI (LODR) Regulations, 2015.

This is to inform you that the Un-audited financial results for the quarter ended June 30, 2018 was approved and taken on records by the Board of Directors at their meeting held on August 14, 2018. The same was signed by Mr. Arihant Baid, Managing Director of the Company and we enclose Un-audited financial results for the quarter ended June 30, 2018 together with Limited Review Report as Annexure – I. We are arranging publication of the results in the newspaper and also in the website of the Company as required under Reg.33 read with 47 of SEBI (LODR) Regulations, 2015.

The Meeting commenced at 11.00 A.M. and concluded at. 03.45 P.M.

Kindly bring this to the notice of the members of the Exchange.

Thanking You,

Yours faithfully,  
For Gennex Laboratories Ltd.,

Authorised Signatory

Encl: as above

**GENNEX LABORATORIES LIMITED**

REGD. OFF: SURVEY NO. 133, BOLLARAM, JINNARAM MANDAL, MEDAK DIST - 502 325

Tel. No. +91-40-67334400-30, Fax: +91-40-67334433, Email: info@gennexlab.com website: www.gennexlab.com

CIN: L24230TG1990PLC011168

Statement of Standalone unaudited Financial Results for the Quarter and Year ended 30th June, 2018.

Sl. No.	Particulars	Quarter Ended			Year ended
		30.06.2018	31.03.2018	30.06.2017	31.03.2018
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	<b>Income</b>				
	(a) Revenue from Operations	944.49	1,347.27	792.08	4,377.88
	(b) Other Income	14.43	72.71	2.18	90.36
	<b>Total Income</b>	<b>958.92</b>	<b>1,419.98</b>	<b>794.26</b>	<b>4,468.24</b>
2	<b>Expenses</b>				
	(a) Cost of materials consumed	618.98	774.41	544.52	2,567.72
	(b) Purchases of stock-in-trade	-	16.50	-	30.01
	(c) Changes in stock-in-trade and work-in-progress and stock-in-trade	(97.17)	131.65	(152.27)	75.42
	(d) Employees Cost	128.09	184.11	118.33	554.58
	(e) Finance Cost	16.99	23.67	14.55	73.11
	(e) Depreciation and amortisation expense	24.02	18.82	22.98	92.18
	( f ) Other Expenses	220.64	251.62	210.79	930.88
	<b>Total expenses</b>	<b>911.54</b>	<b>1,400.78</b>	<b>758.89</b>	<b>4,323.90</b>
3	<b>Total Profit before exceptional items and tax (1-2)</b>	<b>47.37</b>	<b>19.20</b>	<b>35.37</b>	<b>144.34</b>
4	Exceptional items	-	-	-	(1.00)
5	<b>Total Profit before tax (3-4)</b>	<b>47.37</b>	<b>19.20</b>	<b>35.37</b>	<b>145.34</b>
6	Tax expenses for earlier years	-	(40.72)	(0.81)	(61.13)
7	Current Tax	-	(35.00)	-	(35.00)
8	Deferred tax	-	34.37	-	34.37
9	<b>Total Tax expense</b>	<b>-</b>	<b>(41.35)</b>	<b>(0.81)</b>	<b>(61.76)</b>
10	Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	-	-	-	-
11	<b>Net Profit for the period from continuing operation (5-9)</b>	<b>47.37</b>	<b>(22.15)</b>	<b>34.56</b>	<b>83.58</b>
12	Profit(loss) from discontinued operations before tax	-	-	-	-
13	Tax expense of discontinued operations	-	-	-	-
14	<b>Net Profit(loss) from discontinued operations after tax</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
15	Share of profit(loss) of associates and joint ventures accounted for using equity method	-	-	-	-
16	<b>Total profit(loss) for period</b>	<b>47.37</b>	<b>(22.15)</b>	<b>34.56</b>	<b>83.58</b>
17	Other comprehensive Income net of taxes	-	-	-	-
18	<b>Net Profit/(Loss) for the Period</b>	<b>47.37</b>	<b>(22.15)</b>	<b>34.56</b>	<b>83.58</b>
19	<b>Paid-up Equity Share Capital</b> (Face value Rs. 1 each Equity Share) Other Equity	<b>1,265.03</b>	<b>1,265.03</b>	<b>1,265.03</b>	<b>1,265.03</b> <b>191.72</b>
20	<b>Earning Per Equity Share (EPS) (Face value of Rs 1 per Share)</b> ( of Rs. 1 each ) (not annualised) :				
	(a) Basic	0.04	(0.02)	0.03	0.07
	(b) Diluted	0.04	(0.02)	0.03	0.07

**NOTES to the results:**

- 1) The above unaudited financial results for the quarter ended 30 June 2018 have been reviewed by the Audit Committee of the Board of Directors and taken on record at the meeting of Board of Directors held on August 14, 2018 and the
- 2) The Auditors of the Company have carried out the limited review of the above unaudited financial results.
- 3) The Company has adopted Indian Accounting Standards (Ind AS) with effect from April 01,2017 as notified by the Ministry of Corporate Affairs and accordingly the financial results for the quarter and year ended March 31,2017 are in compliance to the said standards. The above statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules,2015 (as amended) prescribed under Section 133 of the Companies Act,2015 read with the rule 3 of the Companies (Indian Accounting Standards) Rules,2015 and SEBI Circular No. CR/CFD/FAC/62/2016 DATED July 05,2016. Consequently, results for the quarter ended 30 June 2017 and 31 March 2018 have been restated/regrouped/re-casted to comply with Ind AS to make them comparable.
- 4) Provision for Taxation & IAS-12 Deferred Tax will be made at the end of the year.
- 5) Adjustment of actuarial valuation in respect of compliance with revised Accounting Standard - IAS - 19 - 'Employee Benefits' is to be done at the year end.
- 6) The results pertaining to the relevant period of the previous year and year ended March,31,2018 stated in Ind AS format have not been subjected to limited review or audit. However,the management has exercised necessary due diligence to ensure the financial results provided a true and fair view of its affairs.
- 7) The Reconciliation between net profit or loss reported in accordance with Indian GAAP (previous GAAP) and Ind AS for the quarter ended 30 June 2018 is as follows:

Particulars	Quarter Ended			Year ended
	30.06.2018	31-03-2018	30.06.2017	31.03.2018
	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Net profit reported for the quarter earlier as per the previous Indian GAAP	47.37	(22.15)	34.56	83.58
Re-measurement of actuarial loss on defined benefit plan	-	-	-	-
Net profit for the period as per Ind AS	47.37	(22.15)	34.56	83.58
Other Comprehensive Income	-	-	-	-
Re-measurement of actuarial loss on defined benefit plan	-	-	-	-
Total Comprehensive Income for the period as per Ind AS	47.37	(22.15)	34.56	83.58

- 8) The management has assessed the Identification of reportable segments in accordance with the requirement of the Ind AS 108 Operating Segment and believes that the Company has only one reportable segment namely " Bulk Drugs, Biotech Products and Intermediates".

For and on behalf of the Board  
For Gennex Laboratories Limited  
sd/-  
Arihant Baid  
Managing Director

Place: Hyderabad  
Date: 14.08.2018

**GENNEX LABORATORIES LIMITED**

REGD. OFF: SURVEY NO. 133, BOLLARAM, JINNARAM MANDAL, MEDAK DIST - 502 325

Tel. No.+91-40-67334400-30, Fax: +91-40-67334433, Email: info@gennexlab.com website: www.gennexlab.com

CIN: L24230TG1990PLC011168

Statement of Consolidated unaudited Financial Results for the Quarter and Year ended 30th June, 2018.

Sl. No.	Particulars	(RS IN LACS)			
		Quarter Ended		Year ended	
		30.06.2018 (Unaudited)	31.03.2018 (Audited)	30.06.2017 (Unaudited)	31.03.2018 (Audited)
1	<b>Income</b>				
	(a) Revenue from Operations	944.49	1,347.27	792.08	4,377.88
	(b) Other Income	14.43	72.71	2.18	90.36
	<b>Total Income</b>	<b>958.92</b>	<b>1,419.98</b>	<b>794.26</b>	<b>4,468.24</b>
2	<b>Expenses</b>				
	(a) Cost of materials consumed	618.98	774.41	544.52	2,567.72
	(b) Purchases of stock-in-trade	-	16.50	-	30.01
	(c) Changes in stock-in-trade and work-in-progress and stock-in-trade	(97.17)	131.65	(152.27)	75.42
	(d) Employees Cost	128.09	184.11	118.33	554.58
	(e) Finance Cost	16.99	23.67	14.55	73.11
	(e) Depreciation and amortisation expense	24.02	18.82	22.98	92.18
	( f ) Other Expenses	220.64	251.62	210.79	930.88
	<b>Total expenses</b>	<b>911.54</b>	<b>1,400.78</b>	<b>758.89</b>	<b>4,323.90</b>
3	<b>Total Profit before exceptional items and tax (1-2)</b>	<b>47.37</b>	<b>19.20</b>	<b>35.37</b>	<b>144.34</b>
4	Exceptional items	-	-	-	(1.00)
5	<b>Total Profit before tax (3-4)</b>	<b>47.37</b>	<b>19.20</b>	<b>35.37</b>	<b>145.34</b>
6	Tax expenses for earlier years	-	(40.72)	(0.81)	(61.13)
7	Current Tax	-	(35.00)	-	(35.00)
8	Deferred tax	-	34.37	-	34.37
9	<b>Total Tax expense</b>	<b>-</b>	<b>(41.35)</b>	<b>(0.81)</b>	<b>(61.76)</b>
10	Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	-	-	-	-
11	<b>Net Profit for the period from continuing operation (5-9)</b>	<b>47.37</b>	<b>(22.15)</b>	<b>34.56</b>	<b>83.58</b>
12	Profit(loss) from discontinued operations before tax	-	-	-	-
13	Tax expense of discontinued operations	-	-	-	-
14	<b>Net Profit(loss) from discontinued operations after tax</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
15	Share of profit(loss) of associates and joint ventures accounted for using equity method	-	(0.95)	-	(0.95)
16	<b>Total profit(loss) for period</b>	<b>47.37</b>	<b>(23.10)</b>	<b>34.56</b>	<b>82.63</b>
17	Other comprehensive Income net of taxes	-	-	-	-
18	<b>Net Profit/(Loss) for the Period</b>	<b>47.37</b>	<b>(23.10)</b>	<b>34.56</b>	<b>82.63</b>
19	<b>Paid-up Equity Share Capital</b> (Face value Rs. 1 each Equity Share) Other Equity	<b>1,265.03</b>	<b>1,265.03</b>	<b>1,265.03</b>	<b>1,265.03</b> 191.72
20	<b>Earning Per Equity Share (EPS) (Face value of Rs 1 per Share)</b> ( of Rs. 1 each ) (not annualised) :				
	(a) Basic	0.04	(0.02)	0.03	0.07
	(b) Diluted	0.04	(0.02)	0.03	0.07

**NOTES to the results:**

- 1) The above unaudited financial results for the quarter ended 30 June 2018 have been reviewed by the Audit Committee of the Board of Directors and taken on record at the meeting of Board of Directors held on August 14, 2018 and the
- 2) The Auditors of the Company have carried out the limited review of the above unaudited financial results.
- 3) The Company has adopted Indian Accounting Standards (Ind AS) with effect from April 01,2017 as notified by the Ministry of Corporate Affairs and accordingly the financial results for the quarter and year ended March 31,2017 are in compliance to the said standards. The above statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules,2015 (as amended) prescribed under Section 133 of the Companies Act,2015 read with the rule 3 of the Companies (Indian Accounting Standards) Rules,2015 and SEBI Circular No. CR/CFD/FAC/62/2016 DATED July 05,2016. Consequently, results for the quarter ended 30 June 2017 and 31 March 2018 have been restated/regrouped/re-casted to comply with Ind AS to make them comparable.
- 4) Provision for Taxation & IAS-12 Deferred Tax will be made at the end of the year.
- 5) Adjustment of actuarial valuation in respect of compliance with revised Accounting Standard - IAS - 19 - 'Employee Benefits' is to be done at the year end.
- 6) The results pertaining to the relevant period of the previous year and year ended March,31,2018 stated in Ind AS format have not been subjected to limited review or audit. However,the management has exercised necessary due diligence to ensure the financial results provided a true and fair view of its affairs.
- 7) The Reconciliation between net profit or loss reported in accordance with Indian GAAP (previous GAAP) and Ind AS for the quarter ended 30 June 2018 is as follows:

Particulars	Quarter Ended			Year ended
	30.06.2018	31-03-2018	30.06.2017	31.03.2018
	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Net profit reported for the quarter earlier as per the previous Indian GAAP	47.37	(23.10)	34.56	82.63
Re-measurement of actuarial loss on defined benefit plan	0	0	0	0
Net profit for the period as per Ind AS	47.37	-23.10	34.56	82.63
Other Comprehensive Income	0	0	0	0
Re-measurement of actuarial loss on defined benefit plan	0		0	0
Total Comprehensive Income for the period as per Ind AS	47.37	-23.10	34.56	82.63

- 8) The management has assessed the Identification of reportable segments in accordance with the requirement of the Ind AS 108 Operating Segment and believes that the Company has only one reportable segment namely " Bulk Drugs, Biotech Products and Intermediates".

For and on behalf of the Board  
For Gennex Laboratories Limited  
sd/-  
Arihant Baid  
Managing Director

Place: Hyderabad  
Date: 14.08.2018



**LIMITED REVIEW REPORT**

To  
The Board of Directors,  
Gennex Laboratories Ltd.,  
Hyderabad.


We have reviewed the accompanying statement of unaudited financial results of GENNEX LABORATORIES LIMITED for the Quarter Ended 30<sup>th</sup> June, 2018 ("the Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016. This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above and subject to the non presentation of segment information as required by Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Hyderabad  
Date : 14/08/2018

For PPKG & CO  
Chartered Accountants  
FRN No. 009655S

  
(GIRDHARI LAL TOSHWAL)  
M.No. 205140

